Dr. Deeds
Share
01/28/2026
Spent the weekend doing CEO things and feeling CEO organized ✌️💪
Here we come waltzing again into 2026, which is of to a banger start. Amid the chaotic storm hoping to maintain a needed calm and hopeful presence in our community and the world.
GLP-1s may be entering their oral era 💊
New trials suggest that high-dose oral GLP-1 medications could approach injectable-level weight loss without needles.
📊 In the OASIS-4 trial, 25 mg oral semaglutide led to ~15% weight loss
🧪 New agents like orforglipron represent a completely different, non-peptide oral GLP-1 class
⚖️ May be a great maintenance option
This doesn’t replace injectables, but it does expand access and choice in obesity care.
At Deeds Health, we follow the science closely so patients get evidence, not hype.
🔗 Reference:
OASIS-4 Trial – The Lancet
Click here to claim your Sponsored Listing.
Category
Contact the business
Address
Seattle, WA
